| Index | — | P/E | 70.15 | EPS (ttm) | 0.60 | Insider Own | 0.74% | Shs Outstand | 1.17B | Perf Week | 6.80% |
| Market Cap | 49.05B | Forward P/E | 13.91 | EPS next Y | 3.03 | Insider Trans | -9.44% | Shs Float | 1.11B | Perf Month | 7.07% |
| Enterprise Value | 62.27B | PEG | 3.43 | EPS next Q | 0.72 | Short Float | 2.53% | Perf Quarter | 22.14% | ||
| Income | 706.00M | P/S | 2.83 | EPS this Y | -23.81% | Short Ratio | 4.91 | Perf Half Y | 20.43% | ||
| Sales | 17.31B | P/B | 6.32 | EPS next Y | 51.94% | ROA | 1.77% | Short Interest | 28.07M | Perf YTD | 34.86% |
| Book/sh | 6.66 | P/C | 13.42 | EPS next 5Y | 20.43% | ROE | 9.07% | 52W High | 42.59 -1.17% | Perf Year | 108.06% |
| Cash/sh | 3.14 | P/FCF | 36.39 | EPS past 3/5Y | — | ROIC | 6.79% | 52W Low | 19.98 110.66% | Perf 3Y | 412.67% |
| Dividend Est. | — | EV/EBITDA | 24.00 | Sales past 3/5Y | 4.96% 0.71% | Gross Margin | 52.47% | Volatility | 3.10% 2.58% | Perf 5Y | 315.50% |
| Dividend TTM | — | EV/Sales | 3.60 | EPS Y/Y TTM | — | Oper. Margin | 11.45% | ATR (14) | 1.17 | Perf 10Y | -4.80% |
| Dividend Ex-Date | Nov 27, 2017 | Quick Ratio | 0.67 | Sales Y/Y TTM | 4.13% | Profit Margin | 4.08% | RSI (14) | 63.68 | Recom | 2.63 |
| Dividend Gr. 3/5Y | -14.63% -3.84% | Current Ratio | 0.88 | EPS Q/Q | -96.97% | SMA20 | 3.88% | Beta | 0.97 | Target Price | 47.33 |
| Payout | 0.00% | Debt/Eq | 2.17 | Sales Q/Q | -0.81% | SMA50 | 7.69% | Rel Volume | 1.33 | Prev Close | 41.47 |
| Employees | 32,008 | LT Debt/Eq | 1.59 | Earnings | Nov 03 | SMA200 | 21.72% | Avg Volume | 5.52M | Price | 42.09 |
| IPO Date | Feb 16, 1982 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -61.96% 1.52% | Net Debt/EBITDA | 5.10 | Volume | 7,320,837 | Change | 1.50% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-15-26 | Reiterated | Barclays | Overweight | $42 → $47 |
| Oct-12-26 | Reiterated | Raymond James | Market Perform | $50 |
| Sep-23-26 | Initiated | Oppenheimer | Outperform | $50 |
| Sep-09-26 | Initiated | Leerink | Outperform | $45 |
| Sep-04-26 | Reiterated | UBS | Buy | $42 → $48 |
| Aug-12-26 | Reiterated | Barclays | Overweight | $40 → $42 |
| Jul-28-26 | Reiterated | Piper Sandler | Overweight | $42 → $44 |
| May-06-26 | Reiterated | Barclays | Overweight | $38 → $40 |
| Apr-30-26 | Reiterated | Piper Sandler | Overweight | $41 → $42 |
| Apr-30-26 | Reiterated | UBS | Buy | $28 → $42 |
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 17,314 | 17,257 | 16,544 | 15,845 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 8,232 | 8,320 | 8,481 | 8,200 | — | — | — | — | — | |
| Gross Profit | 9,085 | 8,938 | 8,063 | 7,645 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 4,127 | 3,973 | 3,702 | 3,498 | — | — | — | — | — | |
| Research and Development | 995 | 1,013 | 1,055 | 953 | — | — | — | — | — | |
| Other Operating Expense | 1,977 | 1,794 | 3,609 | 2,761 | — | — | — | — | — | |
| Operating Income | 1,983 | 2,157 | -303 | 433 | — | — | — | — | — | |
| Interest Expense | 902 | 916 | 941 | 1,029 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -361 | -3 | -39 | -26 | — | — | — | — | — | |
| Net Income Before Taxes | 720 | 1,238 | -1,283 | -622 | — | — | — | — | — | |
| Income Taxes | 12 | -180 | 676 | -7 | — | — | — | — | — | |
| Consolidated Net Income | 706 | 1,410 | -1,639 | -559 | — | — | — | — | — | |
| Net Income From Continuing Operations | 708 | 1,418 | -1,959 | -615 | — | — | — | — | — | |
| Net Income | 706 | 1,410 | -1,639 | -559 | — | — | — | — | — | |
| EPS (Recurring) | 0.63 | 1.23 | -1.45 | -0.50 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.63 | 1.23 | -1.45 | -0.50 | — | — | — | — | — | |
| EPS (Diluted) | 0.60 | 1.20 | -1.45 | -0.50 | — | — | — | — | — | |
| EBITDA | 2,594 | 3,141 | 4,431 | 1,558 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 70.15 | 26.01 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.83 | 2.08 | 1.51 | 0.74 | — | — | — | — | — | |
| Gross Margin | 52.47 | 51.79 | 48.74 | 48.25 | — | — | — | — | — | |
| Operating Margin | 11.45 | 12.50 | -1.83 | 2.73 | — | — | — | — | — | |
| Net Margin | 4.08 | 8.17 | -9.91 | -3.53 | — | — | — | — | — | |
| Shares Outstanding | 1,165 | 1,149 | 1,131 | 1,119 | — | — | — | — | — | |
| Market Capitalization | 49,035 | 35,860 | 24,927 | 11,682 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Savage Brian | Interim Chief Legal Officer | Sep 18 '26 | Sale | 38.85 | 7,342 | 285,215 | 8,500 | Sep 22 |
| Savage Brian | Interim Chief Legal Officer | Sep 18 '26 | Option Exercise | 34.70 | 4,503 | 156,254 | 15,842 | Sep 22 |
| MIGNONE ROBERTO | Director | Sep 18 '26 | Sale | 39.06 | 367,600 | 14,356,802 | 0 | Sep 22 |
| Weiss Amir | Chief Accounting Officer | Aug 21 '26 | Option Exercise | 19.61 | 2,500 | 49,025 | 15,571 | Aug 25 |
| Weiss Amir | Chief Accounting Officer | Aug 21 '26 | Sale | 37.62 | 9,445 | 355,301 | 13,071 | Aug 25 |
| Satchi-Fainaro Ronit | Director | Aug 21 '26 | Sale | 37.25 | 415 | 15,459 | 111,986 | Aug 25 |
| Lippman Evan | EVP, Business Development | Aug 17 '26 | Sale | 36.57 | 18,600 | 680,291 | 25,591 | Aug 19 |
| Zaks Tal Zvi | Director | Aug 05 '26 | Sale | 34.87 | 17 | 593 | 73,247 | Aug 10 |
| Jover Placid | See "Remarks" | Aug 03 '26 | Option Exercise | 0.00 | 12,827 | 0 | 19,601 | Aug 05 |
| Jover Placid | See "Remarks" | Aug 03 '26 | Sale | 34.88 | 12,827 | 447,351 | 6,774 | Aug 05 |
| Hughes Eric A | See "Remarks" | Aug 03 '26 | Option Exercise | 0.00 | 52,744 | 0 | 160,455 | Aug 05 |
| Hughes Eric A | See "Remarks" | Aug 03 '26 | Sale | 34.88 | 25,578 | 892,051 | 134,877 | Aug 05 |
| Shields Matthew | EVP, Global Operations | Jun 18 '26 | Sale | 32.19 | 9,989 | 321,547 | 0 | Jun 22 |
| Kalif Eliyahu Sharon | EVP, Chief Financial Officer | Jun 11 '26 | Sale | 34.10 | 106,563 | 3,633,308 | 65,621 | Jun 16 |
| BARER SOL J | Director | Jun 05 '26 | Option Exercise | 0.00 | 21,739 | 0 | 448,011 | Jun 08 |